Trademark: 79081065
Word
ECTYCELL
Status
Dead
Status Code
404
Status Date
Thursday, October 3, 2019
Serial Number
79081065
Registration Number
3939980
Registration Date
Tuesday, April 5, 2011
Mark Type
4000
Filing Date
Friday, October 2, 2009
Published for Opposition
Tuesday, January 18, 2011
Cancellation Date
Thursday, October 3, 2019

Trademark Owner History
CELLECTIS - Original Registrant

Classifications
1 Chemical, biochemical, biotechnological and bacteriological products for use in industry, science, agriculture, horticulture, namely, chemicals used for industrial purposes, polypeptides for in vivo and in vitro genetic engineering, nucleic acid vectors, natural and engineered meganucleases and endonucleases; chemical, biochemical, biotechnological and bacteriological products for use in research and testing laboratories, namely, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological preparations for scientific purposes namely, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; diagnostic preparations for scientific purposes; proteins being raw materials
5 Pharmaceutical, veterinary and sanitary products, namely, foods, dietetic beverages, and beverages for medical purposes, nutritional supplements for medical use, cultures and preparations of microorganisms for medical, pharmaceutical and veterinary purposes, bacteriological preparations for medical, pharmaceutical and veterinary purposes, medicines for veterinary purposes derived from or validated with stem-cell derived biologicals and for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, medicines for human purposes derived from or validated with stem-cell derived biologicals and for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, biological preparations for medical, pharmaceutical and veterinary purposes for grafts, cell therapy and regenerative medicine, for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, chemical and biochemical preparations for medical, pharmaceutical and veterinary purposes for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, chemical-pharmaceutical preparations for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, diagnostic preparations for medical purposes
9 Scientific apparatus and instruments used in the implementation of biochemical analysis and molecular biology techniques, namely, automated biochemical analyzer, automated protein production and protein purification devices, biochemical, biological automated assay devices, nucleic acid break analyzer, devices for protein-nucleic acid interaction analysis; scientific apparatus and instruments for the mapping of all molecules' biological activities; data processing apparatus; multimedia products, namely, blank magnetic, blank optical, blank image and blank sound recording media; software for recording scientific and medical data on an on-line computer database in the field of pharmaceuticals and biotechnology, for simulation and design of biological and chemical products; apparatus and instruments for non-medical diagnosis, namely, computer hardware, microscopes, spectrometers
42 Scientific research and industrial research in the field of genome engineering, protein engineering; scientific research in the field of genetics, medical, pharmaceutical and veterinary research; scientific research in the field of biology, biochemistry, molecular biology, bacteriology; scientific analysis; scientific research and development of biochemical, biological and molecular biology analysis techniques; research and development of new molecules for industrial use, scientific laboratory services, namely, isolation and preparation of stem cells; laboratory services, namely, imaging core lab services; engineering services, particularly technical project planning; computer programming, computer software and multimedia software design and development
45 Intellectual property licensing; patent licensing

Trademark Events
Apr 17, 2020
Notification Of Effect Of Cancellation Of Intl Reg Mailed
Apr 17, 2020
Death Of International Registration
May 2, 2019
Change Of Name/Address Rec'd From Ib
Sep 14, 2018
Total Invalidation Processed By The Ib
Jul 19, 2018
Total Invalidation Of Reg Ext Protection Sent To Ib
Jul 19, 2018
Invalidation Processed
Jul 10, 2018
Total Invalidation Of Reg Ext Protection Created
Nov 10, 2017
Cancelled Section 71
Mar 27, 2014
New Representative At Ib Received
May 19, 2013
Final Decision Transaction Processed By Ib
Feb 28, 2013
Teas Change Of Correspondence Received
Aug 29, 2011
Final Disposition Notice Sent To Ib
Aug 29, 2011
Final Disposition Processed
Jul 5, 2011
Final Disposition Notice Created, To Be Sent To Ib
Apr 5, 2011
Registered-Principal Register
Jan 18, 2011
Published For Opposition
Dec 29, 2010
Notice Of Publication
Dec 13, 2010
Law Office Publication Review Completed
Dec 13, 2010
Approved For Pub - Principal Register
Nov 19, 2010
Teas/Email Correspondence Entered
Nov 19, 2010
Correspondence Received In Law Office
Nov 19, 2010
Assigned To Lie
Nov 4, 2010
Teas Response To Office Action Received
Jun 18, 2010
Refusal Processed By Ib
May 7, 2010
Non-Final Action Mailed - Refusal Sent To Ib
May 7, 2010
Refusal Processed By Mpu
May 5, 2010
Non-Final Action (Ib Refusal) Prepared For Review
May 4, 2010
Non-Final Action Written
Apr 27, 2010
Application Filing Receipt Mailed
Apr 23, 2010
Assigned To Examiner
Apr 23, 2010
New Application Office Supplied Data Entered In Tram
Apr 22, 2010
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24